8月11日,英派药业(07630.HK)发布盈利预告,公司预计2026年上半年收入约9470万元至1.16亿元,较去年同期约2520万元增长约276%至359%;预计期内亏损约8170万元至9990万元,较去年同期约1.29亿元减少约22%至37%。 公告提到,公司报告期内收入增加主要由于受塞纳帕利于2026年初纳入国家医保药品目录所带动,其商业化进程加快,显著扩大患者用药可及性并带动销量大幅...
Source Link8月11日,英派药业(07630.HK)发布盈利预告,公司预计2026年上半年收入约9470万元至1.16亿元,较去年同期约2520万元增长约276%至359%;预计期内亏损约8170万元至9990万元,较去年同期约1.29亿元减少约22%至37%。 公告提到,公司报告期内收入增加主要由于受塞纳帕利于2026年初纳入国家医保药品目录所带动,其商业化进程加快,显著扩大患者用药可及性并带动销量大幅...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.